Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 1/20 | 0.49 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.48 |
| ▸ | CA2 | P00918 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA3 | P07451 | 1/20 | 0.48 |
| ▸ | CA6 | P23280 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.48 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.44 |
| ▸ | MMP3 | P08254 | 1/20 | 0.43 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.43 |
| ▸ | NOS3 | P29474 | 3/20 | 0.42 |
| ▸ | NOS1 | P29475 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL320277 | 1.00 | PGR (0.49) | PGRCYP2A6CA2ALDH1A1CA12 | |
| SCHEMBL4728041 | 1.00 | PGR (0.49) | PGRCYP2A6CA2ALDH1A1CA12 | |
| SCHEMBL8019149 | 0.94 | MMP3 (0.54) | PGRCYP2A6CA2ALDH1A1CA12 | |
| SCHEMBL15981026 | 0.88 | PARP15 (0.50) | PGRALDH1A1CYP19A1MMP3KDM4E | |
| SCHEMBL2296391 | 0.82 | CYP2A6 (0.44) | CYP2A6CA2ALDH1A1CA12CA3 | |
| SCHEMBL25920912 | 0.82 | CYP2A6 (0.44) | CYP2A6CA2ALDH1A1CA12CA3 | |
| SCHEMBL17902413 | 0.82 | CYP2A6 (0.44) | CYP2A6CA2ALDH1A1CA12CA3 | |
| SCHEMBL15617720 | 0.82 | CYP2A6 (0.44) | CYP2A6CA2ALDH1A1CA12CA3 | |
| SCHEMBL7799578 | 0.80 | CYP2A6 (0.52) | CYP2A6CA2ALDH1A1CA12CA3 | |
| SCHEMBL13557870 | 0.80 | CYP2A6 (0.52) | CYP2A6CA2ALDH1A1CA12CA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113563759-B | Graphene and nano-silver composite material and preparation method thereof | 中国科学院山西煤炭化学研究所 | 2022-11-25 | — | — | CN | claimed |
| CN-113563759-A | Graphene and nano-silver composite material and preparation method thereof | 中国科学院山西煤炭化学研究所 | 2021-10-29 | — | — | CN | claimed |
| CN-111135161-A | Application and preparation method of perfoliate knotweed herb extract with anti-tumor activity | 谭竞 | 2020-05-12 | — | — | CN | claimed |
| CN-119614529-A | Short-chain dehydrogenase, engineering bacteria and application thereof in asymmetric reduction of potential chiral carbonyl compounds | 杭州文德阶生物科技有限公司 | 2025-03-14 | — | — | CN | disclosed |
| US-20240174683-A1 | MAP4K1 INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2024-05-30 | — | — | US | disclosed |
| EP-4288437-A1 | MAP4K1 INHIBITORS | Bayer Aktiengesellschaft (DE) | 2023-12-13 | — | — | EP | disclosed |
| US-20230391812-A1 | RUTHENIUM COMPLEX, PRODUCTION METHOD OF THE COMPLEX, AND PRODUCTION METHOD OF OPTICALLY ACTIVE SECONDARY ALCOHOLS USING THE COMPLEX AS CATALYST | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2023-12-07 | — | — | US | disclosed |
| US-20230285945-A1 | CATALYST CONTAINING ACTIVATED CARBON ADSORBED WITH RUTHENIUM COMPLEX, AND METHOD FOR PRODUCING REDUCTION PRODUCT USING SAME | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2023-09-14 | — | — | US | disclosed |
| EP-4230603-A1 | RUTHENIUM COMPLEX, METHOD FOR PRODUCING SAID COMPLEX, AND METHOD FOR PRODUCING OPTICALLY ACTIVE SECONDARY ALCOHOL USING SAID COMPLEX AS CATALYST | Takasago International Corporation (JP) | 2023-08-23 | — | — | EP | disclosed |
| EP-4230603-A1 | RUTHENIUM COMPLEX, METHOD FOR PRODUCING SAID COMPLEX, AND METHOD FOR PRODUCING OPTICALLY ACTIVE SECONDARY ALCOHOL USING SAID COMPLEX AS CATALYST | Takasago International Corporation (JP) | 2023-08-23 | — | — | EP | disclosed |
| CN-116323522-A | Ruthenium complex, process for producing the same, and process for producing optically active secondary alcohol using the same as catalyst | 高砂香料工业株式会社 | 2023-06-23 | — | — | CN | disclosed |
| US-20090215778-A1 | Alpha-substituted Arylmethyl Piperazine Pyrazolo [1,5-alpha]Pyrimidine Amide Derivatives | PANACOS PHARMACEUTICALS, INC. (US) | 2009-08-27 | — | — | US | disclosed |
| US-20090215778-A1 | Alpha-substituted Arylmethyl Piperazine Pyrazolo [1,5-alpha]Pyrimidine Amide Derivatives | PANACOS PHARMACEUTICALS, INC. (US) | 2009-08-27 | — | — | US | disclosed |
| CN-101503729-A | Enzymatic resolution method of dl 1-phenylethanol compounds | UNIV ZHEJIANG (CN) | 2009-08-12 | — | — | CN | disclosed |
| WO-2008134036-A1 | ALPHA-SUBSTITUTED ARYLMETHYL PIPERAZINE PYRAZOLO[1,5-α]PYRIMIDINE AMIDE DERIVATIVES | PANACOS PHARMACEUTICALS, INC. (US) | 2008-11-06 | — | — | WO | disclosed |
| US-20080227978-A1 | Converting a carbonyl group within a substrate to a chiral alcohol moiety by reacting the carbonyl containing substrate with an organoaluminium reagent in the presence of a Group 5-12 transition metal based catalyst which is complexed with a chiral ligand; excellent yields | THE UNIVERSITY OF NOTTINGHAM | 2008-09-18 | — | — | US | disclosed |
| US-6380218-B1 | FOR THERAPY OF RESPIRATORY, ALLERGIC, AND INFLAMMATORY DISORDERS COMPRISING ASTHMA, CHRONIC OBSTRUCTIVE PULMONARY DISEASE, ACUTE RESPIRATORY DISEASE SYNDROME, PULMONARY HYPERSENSITIVITY, AND ALLERGIC RHINITIS IN A MAMMAL | PFIZER INC | 2002-04-30 | — | — | US | disclosed |
| CN-1254335-A | Nicotinamide derivatives | PFIZER PROD INC (US) | 2000-05-24 | — | — | CN | disclosed |
| EP-0971894-A1 | NICOTINAMIDE DERIVATIVES | Pfizer Products Inc. (US) | 2000-01-19 | — | — | EP | disclosed |
| WO-1998045268-A1 | NICOTINAMIDE DERIVATIVES | PFIZER PRODUCTS INC. (US) | 1998-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215778-A1 | Alpha-substituted Arylmethyl Piperazine Pyrazolo [1,5-alpha]Pyrimidine Amide Derivatives | THPO, DPYD, TPMT | PGR 440/4885CYP2A6 191/4885CA2 4849/4885 |
| US-20240174683-A1 | MAP4K1 INHIBITORS | MAP3K4, MAP4K4, MAP4K1 | PGR 2114/4885CYP2A6 4000/4885CA2 4104/4885 |
| US-20230285945-A1 | CATALYST CONTAINING ACTIVATED CARBON ADSORBED WITH RUTHENIUM COMPLEX, AND METHOD FOR PRODUCING REDUCTION PRODUCT USING SAME | RRS1, POR, SCO2 | PGR 2852/4885CYP2A6 518/4885CA2 244/4885 |
| US-20080227978-A1 | Converting a carbonyl group within a substrate to a chiral alcohol moiety by reacting the carbonyl containing substrate with an organoaluminium reagent in the presence of a Group 5-12 transition metal based catalyst which is complexed with a chiral ligand; excellent yields | ADH5, ADH1C, CYP2E1 | PGR 4404/4885CYP2A6 202/4885CA2 940/4885 |
| US-20230391812-A1 | RUTHENIUM COMPLEX, PRODUCTION METHOD OF THE COMPLEX, AND PRODUCTION METHOD OF OPTICALLY ACTIVE SECONDARY ALCOHOLS USING THE COMPLEX AS CATALYST | ADH5, ADH1A, ADH1C | PGR 2393/4885CYP2A6 243/4885CA2 2433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.